Skip to content
    Reviews

    Meta-analysis shows survival benefit with first-line PD-1 therapy in advanced ESCC

    Rothweiler et alCancer reports (Hoboken, N.J.)

    Meta-analysis shows survival benefit with first-line PD-1 therapy in advanced ESCC
    A systematic review and meta-analysis of six phase III randomized clinical trials evaluated the efficacy and safety of first-line programmed cell death protein 1 (PD-1) inhibitor-based therapy compared with chemotherapy alone in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC). The pooling included data from the KEYNOTE-590 (ESCC subgroup), CheckMate-648 (nivolumab-plus-chemotherapy arm), ESCORT-1st, JUPITER-06, ORIENT-15, and RATIONALE-306 trials, representing 4,137 patients randomized across the parent trial reports.
    The primary endpoint of overall survival (OS) was significantly improved with PD-1 inhibitor-based regimens compared to chemotherapy alone (pooled HR 0.68, 95% CI: 0.63–0.74; I² = 0%). Qualitative assessment indicated that the OS benefit was pronounced in PD-L1-high populations; however, cross-trial differences and lack of biomarker assay harmonization prevented formal pooling for PD-L1-low or PD-L1-negative subgroups, leaving the exact magnitude of benefit in those populations uncertain.
    Regarding toxicity, high-grade (grade ≥ 3) treatment-related adverse events occurred frequently in both treatment groups. However, immune-related toxicities were more prevalent in patients receiving PD-1 inhibitor therapy, requiring active clinical surveillance. The authors conclude that these findings reinforce PD-1 inhibitor-based chemoimmunotherapy as a contemporary standard of care for first-line advanced/metastatic ESCC.

    Key Takeaways

    • First-line PD-1 inhibitor-based therapy significantly improved overall survival compared to chemotherapy alone in patients with advanced or metastatic esophageal squamous cell carcinoma (pooled HR 0.68, 95% CI: 0.63–0.74).
    • Qualitative evaluation demonstrated a greater magnitude of survival benefit in PD-L1-high populations, though unharmonized biomarker definitions across trials precluded formal quantitative subgroup pooling.
    • Grade ≥ 3 treatment-related adverse events were common across both control and experimental arms, but immune-related toxicities occurred more frequently with PD-1 inhibitor regimens.
    Read the original sourceCancer reports (Hoboken, N.J.)